No profile data available.
Rallybio Corporation (RLYB) is a healthcare company in the blood disorder treatment drugs industry, based in New Haven, United States, with about 7 full-time employees.
It reported revenue of $636,000 for fiscal year 2024, and net income of -$57.78 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $212,000, down 29.1% from a year before. Its market capitalization was $90.42 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Rallybio reported $636,000 in revenue for fiscal year 2024. In Q3 2025 revenue was $212,000.
$90.42 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Rocket Pharmaceuticals, Inc. (RCKT), Keros Therapeutics, Inc. (KROS), Coherus Oncology, Inc. (CHRS), Emmaus Life Sciences, Inc. (EMMA).